glp 1 pricing GLP-1 Drug Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More GLP‑1 Receptor Agonist Prices List
Description
A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo
Pauling This Pharmacology Consult will focus on GLP-1 receptor agonists that are currently FDA approved for weight loss, including semaglutide (Wegovy, Novo Nordisk) and liraglutide (Saxenda, Novo Nordisk), but other FDA-approved options exist, such as orlistat, naltrexone/bupropion and phentermine/topiramate
About a quarter of non-carriers reached the recommended HbA1c target after six months of treatment, compared with 11.5% of participants with the p.S539W variant and 18.5% of participants with the p.D563G variant
Appetite loss was reported in 5.5% of users across clinical trials
Whether these individuals have a predisposition for PanIN progression that could be uniquely vulnerable to GLP-1 receptor agonism remains unknown
